RxDoctor Payments Data

Christopher Tam, MD

Urology · Reno, NVNPI 1326573874

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (48.3%), food and beverage and education — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Medtronic at 57.5% of the total. 2025 is the largest year on record at $1,836, more than ten times the $16 reported in 2021. That places this record below the midpoint for urology clinicians in NV, where the typical reported total is $2,990.

$2,834in general payments, 2019–2025

Across 38 payments — averaging $74.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Valencia Technologies Corporation$249
  • Laborie Medical Technologies Corp.$201
  • Procept Biorobotics Corporation$155
  • Boston Scientific$123
  • Teleflex LLC$114
  • plus $362 from 8 others

What the payments were for

  • Travel & lodging$1,36948%
  • Food & beverage$1,36648%
  • Education$1004%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,834 in reported general payments places this provider in the 45th percentile of 63 urology providers in Nevada.

See all urology providers in Nevada

Medicare billing

Part B allowed, 2024
$225,427
Medicare patients
612
Services billed
2,931

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron104$73,208
GemtesaVibegron49$40,951
Tamsulosin Hcl362$6,253
Finasteride294$4,070
Testosterone28$2,487
Estradiol41$2,033
Oxybutynin Chloride ErOxybutynin Chloride11$643
Cephalexin194$584
Trospium Chloride11$557
Testosterone Cypionate19$467
Ketorolac Tromethamine23$389
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst28$272
Alfuzosin Hcl ErAlfuzosin Hcl13$197
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav26$160
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim56$152

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$100$73,208104 claims
Sumitomo Pharma America, Inc.Gemtesa$113$40,95149 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 63 urology providers in Nevada.

Other urology in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →